The FDA has approved a once-weekly 2 mg semaglutide injection in conjunction with diet and exercise to lower HbA1c and reduce the risk for cardiovascular events for adults with type 2 diabetes, according to a press release.
As Healio previously reported, the FDA previously approved 0.5 mg and 1 mg once-weekly semaglutide injections (Ozempic, Novo Nordisk) to improve glycemic control in adults with type 2 diabetes in 2017. The latest approval now allows for 2 mg of semaglutide to be prescribed for adults whose target HbA1c is not met with lower doses. Novo Nordisk plans to launch 2 mg